Prashant Jagannath Chaudhari, Aditya Ramchandra Nemade and Atul Arun Shirkhedkar
RSC Adv., 2024,14, 33384-33417
From themed collection:
2024 Reviews in RSC Advances
Abstract
Essential structural motifs for design of Lead against VEGFR-2.
Atukuri Dorababu
RSC Med. Chem., 2024,15, 416-432
Abstract
The review describes anti-VEGFR-2 activity of heterocycles including quinazoles, pyrimidines, isatin and azoles considering SAR for a given set of derivatives. Compounds with potent activity were emphasized with description of structural features.
Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Dalal Z. Husein, Aisha A. Alsfouk, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Eslam B. Elkaeed, Ahmed M. Metwaly and Ibrahim H. Eissa
RSC Adv., 2023,13, 35853-35876
Abstract
This work presents the synthesis and in vitro, and in silico analyses of new thiadiazole derivatives that are designed to mimic the pharmacophoric characteristics of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors.
Ibrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mostafa A. Elhendawy, Murrell Godfrey and Ahmed M. Metwaly
RSC Adv., 2023,13, 23285-23307
Abstract
This study aimed to design anticancer theobromine derivatives inhibiting VEGFR-2.
Reda R. Mabrouk, Arafa Musa, Maged Mohammed Saleh Al Ward, Shaimaa Hussein, Ahmed K. B. Aljohani, Mohamed Ayman El-Zahabi and Alaa Elwan
RSC Adv., 2025,15, 29593-29612
Abstract
A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors.